Morning Report | Broadcom Q2 revenue miss sparks AI de-risking, hits global tech beta
$SMH AI semis de-risking wave $SMH Global tech beta reset $INDA RBI hold, inflow incentives expand $ITA Ukraine aid bill advances $INDA External-shock stance, growth strong
Market Pulse
India Macro
3 events
India macro mix tilts to external-shock management as RBI stays on hold, growth stays strong, and bond-inflow incentives expand.
Latest Development
RBI kept the policy rate at 5.25% but raised FY ending Mar-2027 inflation forecast to 5.1% and cut growth to 6.6%, citing escalating energy prices and geopolitical risks.
Jan–Mar GDP rose 7.8% y/y versus 7.2% consensus and matched the prior quarter, with the Middle East conflict flagged as a downside to growth and upside to inflation via energy disruption.
India will exempt foreign investors and the BIS from bond interest and capital-gains tax from Apr 1, 2026, while RBI broadened non-resident access to government securities and relaxed limits on foreign portfolio investment.
Market reaction
At the time of reporting, USD/INR was around 95.78 and cited as down over 6% YTD, while the 10-year government bond yield was about 6.958%.
Our view
Policy stays steady but more defensive, with India’s growth resilience offset by energy-linked inflation and FX pressure. Key monitor is whether energy-price stress and related outflows persist enough to force tighter financial conditions despite the bond-inflow measures.
What could change our view
Sustained energy-price surge lifts inflation well above RBI comfort, forcing tightening.
Bond-inflow incentives fail to reverse outflows, accelerating rupee depreciation and tightening conditions.
Tickers: $INDA
Macro & Policy Digest
Washington expands Cuba sanctions via new OFAC designations, raising compliance and enforcement risk for banks and shippers with limited direct crude-supply impact.
Latest Development
U.S. Treasury/OFAC designated Cuba’s President Miguel Díaz-Canel, his wife, and three others, freezing U.S.-jurisdiction property and prohibiting U.S. persons from dealings effective with the 2026-06-05 update.
Secretary of State Rubio announced expanded Cuba-related sanctions on ICAP and linked entities, naming MINFAR, CDR, Minera La Victoria, and Amistur Cuba, and warning U.S. groups and foreign banks servicing designees risk sanctions.
Our view
These Cuba-focused designations stay targeted and do not materially tighten global crude supply, keeping oil sensitivity modest versus broader macro drivers. Monitor for expanded enforcement that constrains shipping/financing around Cuba or broader secondary-sanctions language that pulls in non-U.S. intermediaries.
What could change our view
OFAC actions broaden from individuals to measures restricting fuel shipments or payments.
Secondary-sanctions warnings prompt foreign banks to cut trade finance abruptly.
Tickers: $CL=F
Strait of Hormuz tanker flows thaw modestly without U.S. escorts, but traffic stays far below prewar amid U.S.-Iran clash risk.
Latest Development
Lloyd’s List estimates nearly 40 previously stranded vessels exited the Persian Gulf via Hormuz in three weeks; some filed plans with NCAGS Bahrain, with no U.S. escorts after May’s Project Freedom end.
Market reaction
Oil prices briefly spiked earlier this week amid reported U.S.-Iran clashes around Hormuz, including drone launches toward civilian mariners, U.S. shoot-downs, and subsequent U.S. strikes.
Our view
Crude keeps a modest geopolitical risk premium as transit recovers only partially and security remains self-managed by operators. The key monitor is whether clashes near Hormuz re-accelerate or policy shifts on escorts/sanctions change perceived shipping safety fast.
What could change our view
Sustained attacks on civilian shipping near Hormuz disrupt transits and lift crude sharply.
De-escalation or a reinstated U.S. escort effort normalizes traffic and compresses risk premium.
Tickers: $CL=F
Broadcom’s fiscal Q2 revenue miss triggered an AI-semiconductor de-risking wave, dragging SMH and spilling into Asia and Europe tech stocks.
Latest Development
Broadcom’s revenue miss drove a broad AI-linked semiconductor selloff: AVGO ~-12%, MU nearly -8%, ARM ~-4%, SMH down >1%, with spillover to Samsung -6.4%, SK Hynix ~-9% to -10%, and Europe tech lower early.
Market reaction
AI/semis sold off sharply on the print: AVGO ~-12%, MU nearly -8%, ARM ~-4%, and SMH down >1%; spillover hit Asia (Samsung -6.4%, SK Hynix ~-9% to -10%) and Europe (Stoxx 600 Tech ~-2% early, Infineon -4%, ASML -2.5%). U.S. tape showed rotation with Dow +1.73% while Nasdaq -0.09%.
Our view
A near-term positioning/valuation reset in semis rather than a clean trend break, keeping SMH choppy and headline-sensitive. The next driver is follow-through in guidance and commentary on AI capex, chip pricing, and customer concentration after the Broadcom read-through.
What could change our view
Evidence of broad AI spending slowdown or delayed rollouts across key customers.
Further negative guidance that confirms more than a one-off Broadcom disappointment.
Tickers: $SMH
Ukraine aid and Russia-sanctions bill advances in House, shifting focus to Senate odds and potential veto implications for defense and energy-sensitive names.
Latest Development
The House passed the Ukraine Support Act 226–195, authorizing up to $8bn in FMF loans plus over $1bn other support and new Russia sanctions; it now goes to the Senate amid a stated White House veto threat.
Our view
Near-term market impact stays muted as the bill remains probability-weighted against enactment given uncertain Senate support and an explicit veto threat. Focus on whether the Senate advances a version that can clear the White House or alters the sanctions mandate.
What could change our view
Senate passage coupled with President Trump signing, raising enactment probability sharply.
Mandatory sanctions provisions survive negotiations, materially increasing pressure on Kremlin energy profits.
Tickers: $ITA
Company Events
Retail-heavy SpaceX IPO plans and Quantinuum’s upsized debut highlight robust issuance appetite but signal higher volatility and selectivity for new listings.
Latest Development
SpaceX’s filing outlines a potential mega-cap IPO with up to ~25% allocated to retail on an estimated ~$75bn float, explicitly routing orders through HOOD, SOFI, SCHW, E*Trade and Fidelity with volatility warnings.
Quantinuum priced its IPO at $60 above the $53–$55 range, raising $1.68B; shares opened at $68, traded up to $71.35, and ended roughly flat, implying ~$15.7B value as HON retains majority ownership.
Market reaction
Quantinuum’s first day traded with a strong open versus IPO price ($68 vs $60) and an intraday high of $71.35, before finishing little changed, signaling demand but a restrained close.
Our view
The IPO window stays open, with demand strongest for marquee names while aftermarket trading remains choppy when retail participation is elevated. Watch for retail order-flow capture across the named broker platforms and any indications of timing/scale around Honeywell’s retained-stake monetization.
What could change our view
Retail-driven volatility spikes and deters participation, weakening IPO aftermarket and pipeline.
Earlier-than-expected Honeywell stake sales create overhang and pressure sentiment.
Tickers: $HOOD, $HON
Two small-cap issuers tap equity markets: NYXH launches a U.S. underwritten share offering, LIQT prices $20m at $1.00.
Latest Development
Nyxoah commenced a proposed U.S. underwritten ordinary-share offering off its effective Form F-3 shelf, with a possible concurrent non-U.S. private placement and a 30-day 15% greenshoe.
LiqTech priced an underwritten offering of 20,000,000 shares at $1.00 for about $20.0m gross, with a 45-day 3,000,000-share option; closing is expected June 8 and proceeds target note repayment and growth.
Our view
We expect issuance-related supply to keep NYXH and LIQT trading headline-driven into final terms/close, with any sustained upside requiring clean execution and clearer visibility on commercialization/growth spending and balance-sheet impact. Watch NYXH sizing/pricing in the prospectus supplement and LIQT’s June 8 close plus any over-allotment take-up.
What could change our view
NYXH pricing or sizing comes materially worse than expected, extending the overhang.
LIQT closing slips or greenshoe is fully exercised, increasing dilution beyond expectations.
Tickers: $NYXH, $LIQT
Lululemon reset FY2026 guidance lower as North America demand stays pressured after negative brand commentary and weak launches, raising discounting and tariff margin risk.
Latest Development
Lululemon cut FY2026 revenue to $11.0B–$11.15B and EPS to $10.95–$11.15, and guided fiscal Q2 below Street as Americas comps fell 5% while international revenue rose 22%.
Our view
LULU faces a multi-quarter North America reset with margin pressure as it works through softer traffic and less productive product launches. Monitor whether demand trends recover after management says negative narratives have subsided, versus continued need for discounting into Q2 and FY2026.
What could change our view
North America demand reaccelerates faster than guided, limiting markdowns and lifting margins.
Deeper discounting or tariff impacts drive downside to FY2026 EPS beyond revised range.
Tickers: $LULU
Blackstone’s BCRED hits quarterly redemption cap after Q2 requests spike, reigniting liquidity-mismatch concerns across semi-liquid private credit and alts managers.
Latest Development
Blackstone capped BCRED quarterly repurchases at 5% after Q2 redemption requests reached about 10% of shares, following a Q1 record 7.9% request rate that was fully met via a temporary cap increase.
Our view
This is a contained fund-level liquidity-management headline that raises a near-term sentiment overhang on listed alts, not an immediate credit-event signal. Monitor whether redemption pressure persists into the next quarter and whether more private vehicles implement caps, which would increase fundraising and fee-growth risk.
What could change our view
Redemption requests stay elevated, forcing repeated gating and signaling structural liquidity mismatch.
Contagion broadens as peers restrict withdrawals, tightening fundraising and fee outlooks across managers.
Tickers: $BX
Gilead closes Ouro Medicines deal to expand inflammation pipeline, paying $1.675B upfront plus milestones while ceding development roles and royalties to Lakefront.
Latest Development
Gilead and Lakefront completed the Ouro Medicines acquisition, adding Phase 2 OM336; Gilead pays $1.675B upfront plus up to $500M milestones, with 20%–23% royalties to Lakefront and staged program opt-ins.
Our view
The close reinforces Gilead’s inflammation buildout while keeping near-term risk contained via shared economics and phased development responsibilities. Next key monitor is clinical and regulatory progress for OM336, including how the registrational path and milestone triggers evolve as data mature.
What could change our view
OM336 Phase 1/2 or registrational results disappoint, raising probability of program reprioritization.
Milestone structure and opt-in decisions shift economics away from Gilead’s expected risk-adjusted value.
Tickers: $GILD
Go deeper -
For intraday developments, follow our Midday posts.
For the close, the wrap, and next-day trade ideas, read the Evening Memo.
For deeper work, Forward Valuation covers multi-week single-name setups (paid subscribers only).
Deep Dive is where we publish our full thematic research for paid subscribers.
Informational only; not investment advice. Sources deemed reliable.